Vaccine最新文献

{"title":"Hepatitis B vaccination initiation and vaccination series completion: An in-depth systematic evidence review, with meta-analysis of associations with individual socioeconomic and health-related factors.","authors":"George N. Okoli ,&nbsp;Alexandra Grossman Moon ,&nbsp;Alexandra E. Soos ,&nbsp;Christine J. Neilson ,&nbsp;Diane M. Harper","doi":"10.1016/j.vaccine.2025.127051","DOIUrl":"10.1016/j.vaccine.2025.127051","url":null,"abstract":"<div><h3>Background</h3><div>Associations between hepatitis B vaccination and individual socioeconomic/health-related factors have not been summarised.</div></div><div><h3>Methods</h3><div>We conducted a systematic review with meta-analysis (PROSPERO: CRD42023445721) wherein we grouped study populations into a paediatric population (&lt;18-year-olds), community-dwelling adults (≥18-year-olds of average risk), persons at a higher risk of exposure, and persons with a chronic condition(s). We pooled appropriate multivariable-adjusted results using an inverse variance random-effects model, with the pooled results expressed as odds ratios and associated 95% confidence intervals.</div></div><div><h3>Results</h3><div>We included 83 cross-sectional studies. Thirty-nine studies reported on vaccination initiation, and 51 reported on vaccination series completion. In the paediatric population, being a child of an Asian versus White mother increased the odds of vaccination initiation, whereas a low versus high mother's socioeconomic status and birth in a health facility versus home birth increased the odds of vaccination series completion. In community-dwelling adults, there were increased odds of vaccination initiation with being younger, a White versus Black/Hispanic person, a health professional, higher education, HIV/hepatitis B screening, influenza vaccination in the past year, health insurance, and health care utilisation. There were increased odds of vaccination series completion with factors like initiation. In persons at a higher risk of exposure, older age, higher education, HIV/hepatitis B screening, influenza vaccination in the past year, being married/cohabiting, and training on infection increased the odds of vaccination initiation. In contrast, drug use, HIV/hepatitis B screening, being married/cohabiting, being female, being a current/former smoker, and having more health worker experience increased the odds of vaccination series completion. In persons with chronic condition(s), younger age was associated with increased odds of vaccination initiation, whereas higher education and being a health professional increased the odds of vaccination series completion.</div></div><div><h3>Conclusions</h3><div>Several individual socioeconomic and health-related factors may influence hepatitis B vaccination, particularly in community-dwelling adults and persons at higher risk of exposure. Our findings may inform targeted messaging to optimise hepatitis B vaccination.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"55 ","pages":"Article 127051"},"PeriodicalIF":4.5,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143724064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Distribution of pneumococcal serotypes causing invasive and non-invasive diseases in children in Mexico after introduction of PCV13 (2012−2023). Results from the GIVEBPVac group","authors":"Araceli Soto-Noguerón ,&nbsp;María Noemí Carnalla-Barajas ,&nbsp;Gilberto Sánchez-González ,&nbsp;Fortino Solórzano-Santos ,&nbsp;Mercedes Macías-Parra ,&nbsp;Virginia Díaz-Jiménez ,&nbsp;Damaris Manzano-Arredonda ,&nbsp;Antonino Lara-Barbosa ,&nbsp;Lilia Pichardo-Villalón ,&nbsp;Sarbelio Moreno-Espinoza ,&nbsp;Martha Josefina Avilés-Robles ,&nbsp;Rayo Morfín-Otero ,&nbsp;Antonio Luévanos-Velázquez ,&nbsp;Rosario Vázquez-Larios ,&nbsp;Eduardo Rivera-Martínez ,&nbsp;Mariana Gil-Veloz ,&nbsp;Elvira Garza-González ,&nbsp;Víctor Antonio Monroy-Colín ,&nbsp;José Manuel Feliciano-Guzmán ,&nbsp;Juan Carlos Tinoco-Favila ,&nbsp;Gabriela Echaniz-Aviles","doi":"10.1016/j.vaccine.2025.127031","DOIUrl":"10.1016/j.vaccine.2025.127031","url":null,"abstract":"<div><h3>Background</h3><div>The introduction of pneumococcal conjugate vaccines (PCVs) since 2000 has altered the epidemiology of invasive (IPD) and non-invasive pneumococcal diseases (NIPD). This study aims to analyze trends in pneumococcal serotype distribution among children in Mexico, focusing on the period following the introduction of PCV13, and assess the potential impact of future vaccines.</div></div><div><h3>Material and methods</h3><div>Pneumococcal isolates were collected from hospitalized children in participating hospitals from January 2012 to December 2023. Serotype distribution was analyzed in children under &lt;5 years and those aged ≥5 to 17.9 years. The average annual change (AAC) in serotype proportions was calculated, and trends were analyzed using the Cochran-Armitage test.</div></div><div><h3>Results</h3><div>Serotype 19A was the most frequent PCV13 serotype, followed by serotypes 3 and 19F, in both age groups. Serotype 33F, included in PCV15 and PCV20, was absent in children aged ≥5‐17.9 years. Among PCV20 serotypes, serotype 15B was the most common, and serotype 17F, covered by PCV24, showed a significant increase in the older age group (<em>p</em> = 0.037). No significant trends in the increase or decrease of individual serotypes were found, except for serotypes 17F and serotype 34, which increased in both age groups. A decrease in serotypes covered by PCV13 (excluding serotypes 3, 19A, and 19F) was observed in both age groups (<em>p</em> = 0.04, 0.002). A significant increase in non-PCV13 serotypes occurred in children aged ≥5‐17.9 years (<em>p</em> = 0.023).</div></div><div><h3>Conclusions</h3><div>After a decade of the introduction of PCV13 in Mexico, 10 of the 13 vaccine serotypes have not been detected in the past six years. However, serotypes 3, 19A, and 19F persist at high frequencies as causes of IPD and NIPD in children. Ongoing robust surveillance is critical for identifying emerging pneumococcal serotypes, selecting appropriate vaccines for each country, and developing next-generation vaccine formulations.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"55 ","pages":"Article 127031"},"PeriodicalIF":4.5,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143724161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HAVI: A novel tool to explore vaccine hesitancy among adults in Greece","authors":"Aikaterini S. Stravoravdi ,&nbsp;Aristea I. Ladas ,&nbsp;Christos A. Frantzidis ,&nbsp;Georgios Papazisis","doi":"10.1016/j.vaccine.2025.127042","DOIUrl":"10.1016/j.vaccine.2025.127042","url":null,"abstract":"<div><div>Vaccine hesitancy remains a critical public health challenge, influenced by demographic and cultural factors. In Greece, age and gender are significant determinants. This study aimed to develop and validate a culturally adapted survey instrument, the Hellenic Attitudes towards Vaccination Index (HAVI), to assess beliefs and attitudes towards vaccination among Greek adults. Additionally, the study sought to investigate the impact of gender and age on vaccine hesitancy. By adapting an existing questionnaire, we ensured cultural and linguistic relevance to the Greek context.</div><div>This novel study employed a cross-sectional design, recruiting 184 adults (92 males, mean age = 40.2 years; 92 females, mean age = 38.8 years). Participants completed the 22-item HAVI questionnaire. Data analysis included Exploratory Factor Analysis (EFA), correlation analysis, internal consistency assessment, and regression analysis.</div><div>EFA revealed a four-factor structure: (1) Perceived Vaccine Safety, (2) Perceived Vaccine Effects, (3) Attitudes Towards Health Authorities, and (4) Perceived Benefit of Mandatory Vaccines. A heatmap provided an intuitive visualization of item-factor relationships. The instrument demonstrated excellent reliability (Cronbach's α = 0.92).</div><div>Although explaining small to moderate amount of variance, there were key findings identified significant gender differences, with females showing higher vaccine hesitancy, and an inverse correlation between age and positive vaccination attitudes. HAVI represents a reliable and practical tool for assessing vaccine hesitancy in Greek adults, offering valuable insights to guide targeted public health strategies.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"55 ","pages":"Article 127042"},"PeriodicalIF":4.5,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143724162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An efficient vaccine clinical trial: ACTG A5379 hepatitis B vaccine trial in persons with HIV","authors":"Minhee Kang ,&nbsp;Kristen M. Marks ,&nbsp;Andrea L. Cox ,&nbsp;Kenneth E. Sherman","doi":"10.1016/j.vaccine.2025.127028","DOIUrl":"10.1016/j.vaccine.2025.127028","url":null,"abstract":"<div><div>Clinical trial designs that address multiple questions more efficiently are desirable. When we designed a hepatitis B vaccine trial to assess seroprotective outcomes in persons with HIV (PWH), we aimed for an efficient design that addressed three primary objectives in two study populations. The study focused on: PWH who did not respond to prior HBV vaccination, and PWH with no known history of HBV vaccination. Whereas one vaccine regimen was studied in the vaccine-naïve participants, multiple interventions were considered for those with prior nonresponse, with two different vaccines and two dosing schedules. Several features of the trial design required statistical considerations related to multiple testing: (1) assessment of vaccine response in two study populations under one trial, (2) comparisons among multiple treatment arms, and (3) sequential repeated significance tests in interim data monitoring. We describe the features aimed to gain statistical and administrative efficiencies, including reduction in the study sample size of 12 %. We also describe how we controlled type I error and planned interim data monitoring, and highlight the time lag issue due to the laboratory-based immunogenicity endpoint in this international, multi-center trial (<span><span>NCT04193189</span><svg><path></path></svg></span>).</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"55 ","pages":"Article 127028"},"PeriodicalIF":4.5,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143724163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of a proactive childhood vaccination reminder system on vaccination coverage and uptake in Denmark: A register-based cohort study","authors":"Tjede Funk ,&nbsp;Sarah Kristine Nørgaard ,&nbsp;Louise Hallundbæk ,&nbsp;Julie Grau ,&nbsp;Steen Ethelberg ,&nbsp;Palle Valentiner-Branth ,&nbsp;Peter Henrik Andersen","doi":"10.1016/j.vaccine.2025.126934","DOIUrl":"10.1016/j.vaccine.2025.126934","url":null,"abstract":"<div><h3>Background</h3><div>In August 2019, Denmark implemented a proactive childhood vaccination reminder system. This study aimed to assess the effect of the introduction of this vaccination reminder system on vaccination coverage and uptake of the first four childhood vaccinations, namely the tetanus, diphtheria, acellular pertussis, polio, haemophilus influenzae type b (Hib)-infection vaccination (DTaP-IPV/Hib) recommended at three, five and twelve months as well as mumps, measles, rubella vaccination (MMR1) recommended at 15 months.</div></div><div><h3>Methods</h3><div>This was a retrospective register-based cohort study based on two birth cohorts: children born in January 2018 (i.e. control group) and January 2022 (i.e. intervention group). All children that lived in Denmark and were alive during the entire study period were included. Children were followed-up from two weeks before to six weeks after each scheduled vaccination. The end of the study period was therefore at 16.5 months. Differences in vaccination status were tested at six weeks after scheduled vaccination. The median days to vaccination were calculated and compared between the two cohorts. Kaplan Meier curves and logrank tests were used to compare vaccination uptake over time between the two cohorts. Logistic regression analyses tested for differences in vaccination coverage at six weeks after scheduled vaccination between the study groups. Sensitivity analyses were conducted using alternative birth cohorts.</div></div><div><h3>Results</h3><div>The vaccination coverage at six weeks after scheduled vaccination was higher for children in the intervention cohort for all vaccinations, except the second diphtheria-tetanus-pertussis-polio-Hib vaccine (DTaP-IPV/Hib2) given at 5 months. Fewer children in the intervention cohort were unvaccinated (3.4 % vs 1.3%3 %; <em>p</em> &lt; 0.001) and more children had received all three DTaP-IPV/Hib vaccinations at the end of the study period (88.3 % versus 79.0 %; <em>p</em> &lt; 0.001). Children in the intervention group were significantly more likely to have been vaccinated at six weeks after scheduled vaccination for all vaccinations except DTaP-IPV/Hib2, compared to the control group.</div></div><div><h3>Conclusions</h3><div>This study indicated that the children vaccinated under the proactive vaccination reminder system did have a higher vaccination coverage for three out of four investigated childhood vaccinations and a somewhat quicker vaccination uptake than children vaccinated before the introduction of the reminder system.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"54 ","pages":"Article 126934"},"PeriodicalIF":4.5,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143704620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Parent-daughter agreement about HPV vaccination status in Kenya and Malawi","authors":"Corrina Moucheraud ,&nbsp;Eric Ochieng ,&nbsp;Ansila Kweka ,&nbsp;Pengyun Wang ,&nbsp;Shangkun Xie ,&nbsp;John Ototo ,&nbsp;Ginger Golub ,&nbsp;Ellen Kapindo ,&nbsp;Esau Banda ,&nbsp;Hawa Abdillahi ,&nbsp;Peter G. Szilagyi ,&nbsp;Siyu Heng","doi":"10.1016/j.vaccine.2025.127025","DOIUrl":"10.1016/j.vaccine.2025.127025","url":null,"abstract":"<div><h3>Background</h3><div>As more countries introduce the HPV vaccine, it is important to understand the validity of vaccination measures. This is especially true in low- and middle-income countries (LMICs) where public health monitoring of vaccination data may have delays or gaps, so alternative measurement approaches are often necessary. Parental report is a common approach for measuring routine childhood vaccination, but it has not been evaluated for HPV vaccination in LMICs.</div></div><div><h3>Methods</h3><div>We conducted household surveys in Kenya (<em>n</em> = 146) and Malawi (<em>n</em> = 98) with parents/guardians and their daughters who were age-eligible for HPV vaccination. We compared parents'/guardians' reports of HPV vaccination status to daughters' reports; the latter was assumed to be the “gold standard” measure.</div></div><div><h3>Results</h3><div>88 % of Kenyan parents/guardians and 82 % of Malawian parents/guardians agreed with their daughters' reported HPV vaccination status. It was more common for parents/guardians to under-report (i.e., to say their daughter was unvaccinated but the girl said she had received dose(s)) than the inverse. Agreement with one's daughter was higher among parents/guardians who reported data from vaccination cards versus using recall, and among parents/guardians who expressed more versus less confidence in their knowledge. We did not find many differences in accuracy of report by parent/guardian characteristics, although in Kenya there were small and statistically significant negative associations with parental age, household income, and more girls in the household (the latter was also significantly negatively associated with report accuracy in Malawi).</div></div><div><h3>Conclusions</h3><div>In countries where surveys will commonly be used to measure HPV vaccination status, we found very high agreement of parents/guardians with their daughters' reported receipt of the vaccine. These results are similar to findings from the literature about routine childhood vaccination measurement. This suggests that researchers, clinicians, and practitioners can use parent/guardian-reported HPV vaccination of their daughter as a relatively good proxy of her own reported immunization status especially in settings without universal use of vaccination cards or registries.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"55 ","pages":"Article 127025"},"PeriodicalIF":4.5,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143724160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of HPV-loaded PLGA microparticles as single-dose HPV vaccine: Insights for sustained-release vaccine development","authors":"Yingyue Zhang ,&nbsp;Nicole Sullivan ,&nbsp;Mathew Abraham ,&nbsp;Hyking D. Haley ,&nbsp;Yaping Liu ,&nbsp;Elizabeth Mahan ,&nbsp;Catherine Hines ,&nbsp;Michal Tomaszewski ,&nbsp;Corin O. Miller ,&nbsp;Vasudevan Bakthavatchalu ,&nbsp;Michael McNevin ,&nbsp;Leia Epstein ,&nbsp;Helen Yarovoi ,&nbsp;Elizabeth Marie Shenk ,&nbsp;Donna Williams ,&nbsp;Lisa Plitnick","doi":"10.1016/j.vaccine.2025.127024","DOIUrl":"10.1016/j.vaccine.2025.127024","url":null,"abstract":"<div><div>The human papillomavirus (HPV) vaccine is pivotal to prevent new HPV infections and associated diseases globally, which requires a multi-dose regimen to maximize protection. A long-acting HPV vaccine that can be administered in a single immunization during a doctor's visit would be highly desirable if comparable benefits are provided to that of standard of care (SoC). This work explored the development of a sustained-release HPV vaccine formulation via temperature-programmed loading of polylactic-<em>co</em>-glycolic acid (PLGA) microparticles (MPs). Traditional methods for fabricating HPV-loaded MPs suffer from HPV virus-like particles (VLP) structure/function loss due to exposure to organic solvents, shear stress, etc. This approach separates the microparticle fabrication from VLP loading thereby effectively minimized common stress conditions during formulation. The HPV-loaded PLGA MPs demonstrated significantly prolonged injection site retention as a depot and successfully elicited robust immunogenicity in a dose-dependent manner in vivo. However, a single dose of HPV MPs alone resulted in lower immunogenicity compared to GARDASIL®9 (G9, laboratory prepared material equivalent in composition) prime/boost in a rabbit model, likely due to the lack of an effective adjuvant in the formulation. Alternatively, concomitant administration of HPV MPs and G9 at separate injection sites was shown to induce noninferior antibody titers and durable immune response compared to the current SoC multi-dose regimen. It was hypothesized that the bolus dose of G9 served as potent prime while sustained release of HPV antigens from MPs exerted booster effect. Despite the cost benefits and convenience offered by a single injection of HPV vaccine, the co-formulation of HPV MPs with G9 remains a challenging area. In summary, this work successfully demonstrated the feasibility of developing a sustained-release formulation of HPV vaccine and provided valuable insights into challenges and opportunities of formulation design to improve efficacy, safety, and tolerability as a single-dose HPV vaccine.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"55 ","pages":"Article 127024"},"PeriodicalIF":4.5,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143688034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Refresher training in administering intradermal BCG-vaccine increased BCG-scarring rates in rural Guinea-Bissau","authors":"Julie Odgaard Vedel ,&nbsp;Oides Furtado ,&nbsp;Laerte Lima Almeida ,&nbsp;Jailson Sydenei Dias Martins ,&nbsp;Sanne Møller Thysen ,&nbsp;Andreas Møller Jensen ,&nbsp;Igualdino Da Silva Borges ,&nbsp;Ane Bærent Fisker","doi":"10.1016/j.vaccine.2025.127039","DOIUrl":"10.1016/j.vaccine.2025.127039","url":null,"abstract":"<div><h3>Background</h3><div>A correct vaccination technique is important for developing BCG scars. Having a BCG scar is associated with lower mortality among BCG-vaccinated children.</div></div><div><h3>Aim</h3><div>To compare BCG-scar prevalences among children vaccinated before and after refresher training in BCG vaccination technique.</div></div><div><h3>Methods</h3><div>BCG-scar prevalence is assessed through a health and demographic surveillance system in rural Guinea-Bissau. In the context of a randomised trial, staff at health facilities in three regions (intervention area) received refresher training on BCG vaccination technique. In a fourth region (control area) no training was implemented. In logistic regression models, we compared scar prevalence among children vaccinated before and after the training.</div></div><div><h3>Results</h3><div>BCG-scar prevalence increased from 75 % to 92 % (odds ratio (OR) = 4.19, 95 %CI 2.92–6.01) in the intervention area and from 71 % to 78 % (OR = 1.43, 95 %CI 0.89–2.29) in the control area (<em>p</em>-value for same increase: &lt;0.001).</div></div><div><h3>Conclusion</h3><div>BCG scarring rates increased after training in vaccination technique.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"55 ","pages":"Article 127039"},"PeriodicalIF":4.5,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143724164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Landscape analysis of invasive non-typhoidal salmonella (iNTS) disease and iNTS vaccine use case and demand: Report of a WHO expert consultation","authors":"Kate Emary ,&nbsp;Adwoa D. Bentsi-Enchill ,&nbsp;Birgitte K. Giersing ,&nbsp;Melita Gordon ,&nbsp;Helen Dale ,&nbsp;Esmelda B. Chirwa ,&nbsp;Peter Johnston ,&nbsp;Calman A. MacLennan ,&nbsp;Samuel Kariuki ,&nbsp;Jean-Louis Excler ,&nbsp;Jerome H. Kim ,&nbsp;Robert W. Kaminski ,&nbsp;Annelies Wilder-Smith ,&nbsp;the iNTS vaccine Consultation Expert Group","doi":"10.1016/j.vaccine.2025.127008","DOIUrl":"10.1016/j.vaccine.2025.127008","url":null,"abstract":"<div><div>Invasive disease caused by non-typhoidal <em>Salmonella</em> serovars (iNTS) occurs with increased risk in the presence of other comorbidities such as malaria, HIV, malnutrition, anaemia and sickle cell disease. While infection with non-typhoidal (NTS) serovars often results in self-limited enterocolitis in high-income settings, in sub-Saharan Africa (SSA) where these risk-comorbidities are common, an invasive (iNTS) disease phenotype is seen, associated with up to 20 % case-fatality ratio, and antimicrobial resistance is both significant and growing. The need to evaluate the potential public health value of vaccines against iNTS disease is increasingly being recognized, and several candidate vaccines are in early development. A better understanding of the global burden and epidemiology of iNTS disease, as well as the potential public health and socio-economic benefits that iNTS vaccines may offer is fundamental to support and justify the investments in vaccine development. In addition, the pathways for licensure, policy recommendations and eventual vaccine prioritization and use in low- and middle-income countries (LMICs) need to be defined.</div><div>Here, we report on the proceedings of an expert consultation held on 29 November – 1 December 2021 as part of an overall project to develop a Full Value of Vaccines Assessment (FVVA) for iNTS vaccines and in addition to more recent iNTS vaccine developments. Experts at the consultation reviewed the current evidence on iNTS disease and discussed knowledge gaps to be addressed to accelerate vaccine development, licensure and introduction, as well as LMIC perspectives on potential iNTS vaccine use and demand. The learnings from this consultation are critical inputs to inform remaining work under the iNTS FVVA project.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"55 ","pages":"Article 127008"},"PeriodicalIF":4.5,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143687282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"“It's easier to deal with the vaccines you know than the ones you don't know”: A qualitative study on healthcare workers' vaccine confidence in Nigeria","authors":"Ayobami A. Bakare ,&nbsp;Elisa Gobbo ,&nbsp;Kofoworola O. Akinsola ,&nbsp;Carina King ,&nbsp;Julius Salako ,&nbsp;Damola Bakare ,&nbsp;Halima Usman ,&nbsp;Claudia Hanson ,&nbsp;Adegoke G. Falade ,&nbsp;Sibylle Herzig van Wees","doi":"10.1016/j.vaccine.2025.127020","DOIUrl":"10.1016/j.vaccine.2025.127020","url":null,"abstract":"","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"55 ","pages":"Article 127020"},"PeriodicalIF":4.5,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143687337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}